Cambridge Investment Research Advisors
ACXP icon

Cambridge Investment Research Advisors’s Acurx Pharmaceuticals ACXP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74K Buy
+20,000
New +$56.7K ﹤0.01% 3818
2025
Q3 		– Sell
-4,250
Closed -$43K – 3715
2025
Q2 		$43K Buy
4,250
+3,500
+467% +$28.2K ﹤0.01% 3548
2025
Q1 		$6K Sell
750
-138
-16% -$1.86K ﹤0.01% 3488
2024
Q4 		$14K Buy
+888
New +$26.7K ﹤0.01% 3435
2024
Q3 		– Sell
-500
Closed -$23K – 3410
2024
Q2 		$23K Hold
500
– – ﹤0.01% 3257
2024
Q1 		$25K Buy
+500
New +$32.5K ﹤0.01% 3254

Other funds holding ACXP

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return

Cambridge Investment Research Advisors's ACXP Position: Q1 2026 in Review

Cambridge Investment Research Advisors opened a new position in Acurx Pharmaceuticals (ACXP) in Q1 2026: 20,000 shares worth $74K. The stake represents ﹤0.01% of the portfolio and ranks #3818 among its holdings. This is a return to the name: Cambridge Investment Research Advisors previously reported a position in ACXP as recently as Q2 2025.

Cambridge Investment Research Advisors first reported a position in ACXP in Q1 2024 and has held it in 6 quarters since. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

  • Cambridge Investment Research Advisors held 20,000 shares of Acurx Pharmaceuticals worth $74K as of Q1 2026.
  • Acurx Pharmaceuticals was a new Cambridge Investment Research Advisors position in Q1 2026.
  • Acurx Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3818 holding.
  • Cambridge Investment Research Advisors first reported a position in Acurx Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • 21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.